111 related articles for article (PubMed ID: 8993486)
21. Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia.
Gustafson L; Abrahamson M; Grubb A; Nilsson K; Fex G
Dement Geriatr Cogn Disord; 1997; 8(4):240-3. PubMed ID: 9213069
[TBL] [Abstract][Full Text] [Related]
22. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
Jobst KA; Barnetson LP; Shepstone BJ
Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
[TBL] [Abstract][Full Text] [Related]
23. Patterns of brain activation in people at risk for Alzheimer's disease.
Bookheimer SY; Strojwas MH; Cohen MS; Saunders AM; Pericak-Vance MA; Mazziotta JC; Small GW
N Engl J Med; 2000 Aug; 343(7):450-6. PubMed ID: 10944562
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.
Gomez-Isla T; West HL; Rebeck GW; Harr SD; Growdon JH; Locascio JJ; Perls TT; Lipsitz LA; Hyman BT
Ann Neurol; 1996 Jan; 39(1):62-70. PubMed ID: 8572669
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's disease: clinical implications of the apolipoprotein E genotype.
Farlow MR
Neurology; 1997 May; 48(5 Suppl 6):S30-4. PubMed ID: 9153158
[TBL] [Abstract][Full Text] [Related]
26. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
27. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions.
Egensperger R; Bancher C; Kösel S; Jellinger K; Mehraein P; Graeber MB
Biochem Biophys Res Commun; 1996 Jul; 224(2):484-6. PubMed ID: 8702415
[TBL] [Abstract][Full Text] [Related]
28. Neuroimaging for diagnosis of dementia.
Small GW; Leiter F
J Clin Psychiatry; 1998; 59 Suppl 11():4-7. PubMed ID: 9731543
[TBL] [Abstract][Full Text] [Related]
29. Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.
Mosconi L; Herholz K; Prohovnik I; Nacmias B; De Cristofaro MT; Fayyaz M; Bracco L; Sorbi S; Pupi A
J Neurol Neurosurg Psychiatry; 2005 Jan; 76(1):15-23. PubMed ID: 15607989
[TBL] [Abstract][Full Text] [Related]
30. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
31. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.
Craft S; Asthana S; Schellenberg G; Baker L; Cherrier M; Boyt AA; Martins RN; Raskind M; Peskind E; Plymate S
Ann N Y Acad Sci; 2000 Apr; 903():222-8. PubMed ID: 10818510
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease.
Growdon JH; Locascio JJ; Corkin S; Gomez-Isla T; Hyman BT
Neurology; 1996 Aug; 47(2):444-8. PubMed ID: 8757018
[TBL] [Abstract][Full Text] [Related]
33. APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.
Reinvang I; Espeseth T; Westlye LT
Neurosci Biobehav Rev; 2013 Sep; 37(8):1322-35. PubMed ID: 23701948
[TBL] [Abstract][Full Text] [Related]
34. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease.
Olichney JM; Sabbagh MN; Hofstetter CR; Galasko D; Grundman M; Katzman R; Thal LJ
Neurology; 1997 Jul; 49(1):76-81. PubMed ID: 9222173
[TBL] [Abstract][Full Text] [Related]
35. Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin.
DeKosky ST; Aston CE; Kamboh MI
Ann N Y Acad Sci; 1996 Dec; 802():27-34. PubMed ID: 8993481
[TBL] [Abstract][Full Text] [Related]
36. Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians.
Osuntokun BO; Sahota A; Ogunniyi AO; Gureje O; Baiyewu O; Adeyinka A; Oluwole SO; Komolafe O; Hall KS; Unverzagt FW
Ann Neurol; 1995 Sep; 38(3):463-5. PubMed ID: 7668835
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease.
Corder EH; Saunders AM; Strittmatter WJ; Schmechel DE; Gaskell PC; Rimmler JB; Locke PA; Conneally PM; Schmader KE; Tanzi RE
Neurology; 1995 Jul; 45(7):1323-8. PubMed ID: 7617191
[TBL] [Abstract][Full Text] [Related]
38. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
39. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease.
Saunders AM; Hulette O; Welsh-Bohmer KA; Schmechel DE; Crain B; Burke JR; Alberts MJ; Strittmatter WJ; Breitner JC; Rosenberg C
Lancet; 1996 Jul; 348(9020):90-3. PubMed ID: 8676723
[TBL] [Abstract][Full Text] [Related]
40. Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study.
Mosconi L; Sorbi S; Nacmias B; De Cristofaro MT; Fayyaz M; Bracco L; Herholz K; Pupi A
Psychiatry Res; 2004 Feb; 130(2):141-51. PubMed ID: 15033184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
